LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Abbott Laboratories

Geschlossen

BrancheGesundheitswesen

134.76 1.17

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

132.33

Max

135.15

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.9B

1.3B

Verkäufe

-616M

10B

KGV

Branchendurchschnitt

17.142

56.602

EPS

1.09

Dividendenrendite

1.76

Gewinnspanne

12.792

Angestellte

114,000

EBITDA

-324M

2.7B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+12.32% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.76%

2.45%

Nächste Dividendenausschüttung

14. Aug. 2025

Nächstes Ex-Dividendendatum

14. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.8B

230B

Vorheriger Eröffnungskurs

133.59

Vorheriger Schlusskurs

134.76

Nachrichtenstimmung

By Acuity

33%

67%

101 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Abbott Laboratories Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Apr. 2025, 16:21 UTC

Ergebnisse

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16. Apr. 2025, 12:14 UTC

Ergebnisse

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22. Jan. 2025, 19:03 UTC

Ergebnisse

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22. Jan. 2025, 18:20 UTC

Ergebnisse

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22. Jan. 2025, 12:45 UTC

Ergebnisse

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16. Apr. 2025, 15:09 UTC

Market Talk

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16. Apr. 2025, 14:17 UTC

Ergebnisse

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16. Apr. 2025, 11:34 UTC

Ergebnisse

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16. Apr. 2025, 11:33 UTC

Ergebnisse

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16. Apr. 2025, 11:32 UTC

Ergebnisse

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16. Apr. 2025, 11:32 UTC

Ergebnisse

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16. Apr. 2025, 11:31 UTC

Ergebnisse

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Reaffirms Full-Yr Guidance

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Sales $10.36B >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Net $1.33B >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q EPS 76c >ABT

16. Apr. 2025, 11:30 UTC

Ergebnisse

Abbott Labs 1Q Adj EPS $1.09 >ABT

16. Apr. 2025, 09:57 UTC

Heiße Aktien

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1. Feb. 2025, 18:14 UTC

Top News

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22. Jan. 2025, 16:40 UTC

Top News
Ergebnisse

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22. Jan. 2025, 15:20 UTC

Ergebnisse

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22. Jan. 2025, 15:08 UTC

Ergebnisse

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. Jan. 2025, 13:51 UTC

Ergebnisse

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22. Jan. 2025, 13:39 UTC

Top News
Ergebnisse

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. Jan. 2025, 12:02 UTC

Ergebnisse

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22. Jan. 2025, 12:01 UTC

Ergebnisse

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22. Jan. 2025, 12:01 UTC

Ergebnisse

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22. Jan. 2025, 12:00 UTC

Ergebnisse

Abbott Labs 4Q Net $9.23B >ABT

Peer-Vergleich

Kursveränderung

Abbott Laboratories Prognose

Kursziel

By TipRanks

12.32% Vorteil

12-Monats-Prognose

Durchschnitt 144.4 USD  12.32%

Hoch 159 USD

Tief 127 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Abbott Laboratories – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

21 ratings

18

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

132.82 / 134.43Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

101 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.